DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Purchases $3,000,000.00 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) major shareholder Koch Thomas Von bought 1,200,000 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was purchased at an average price of $2.50 per share, with a total value of $3,000,000.00. Following the completion of the transaction, the insider now directly owns 5,526,435 shares in the company, valued at approximately $13,816,087.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

DiaMedica Therapeutics Price Performance

DMAC stock remained flat at $2.95 during trading on Monday. 236,702 shares of the company were exchanged, compared to its average volume of 48,892. DiaMedica Therapeutics Inc. has a twelve month low of $1.94 and a twelve month high of $4.45. The business’s fifty day moving average is $2.77 and its 200-day moving average is $2.82. The company has a market capitalization of $111.99 million, a P/E ratio of -4.82 and a beta of 1.74.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. As a group, research analysts forecast that DiaMedica Therapeutics Inc. will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at $36,000. Stonebridge Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at $52,000. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in shares of DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after purchasing an additional 211,351 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DMAC shares. Craig Hallum started coverage on shares of DiaMedica Therapeutics in a research report on Wednesday, April 24th. They set a “buy” rating and a $8.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and set a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.